The other shoe drops for Immunic

As if being overtaken by a rival mechanism of action had not been enough, Immunic now has to contend with clinical failure. The company’s RORγ inverse agonist IMU-935 yesterday flunked its proof-of-concept trial in psoriasis, an event SVB Securities had recently described as Immunic’s most important near-term catalyst.